DE60224592D1 - Polymorph und andere kristallinische Formen von Zusammen-FTC - Google Patents

Polymorph und andere kristallinische Formen von Zusammen-FTC

Info

Publication number
DE60224592D1
DE60224592D1 DE60224592T DE60224592T DE60224592D1 DE 60224592 D1 DE60224592 D1 DE 60224592D1 DE 60224592 T DE60224592 T DE 60224592T DE 60224592 T DE60224592 T DE 60224592T DE 60224592 D1 DE60224592 D1 DE 60224592D1
Authority
DE
Germany
Prior art keywords
ftc
forms
cis
manufacture
polymorph
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60224592T
Other languages
English (en)
Other versions
DE60224592T2 (de
Inventor
Kenneth R Phares
Devalina Law
Yuerong Hu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Gilead Sciences Inc
Original Assignee
Abbott Laboratories
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories, Gilead Sciences Inc filed Critical Abbott Laboratories
Publication of DE60224592D1 publication Critical patent/DE60224592D1/de
Application granted granted Critical
Publication of DE60224592T2 publication Critical patent/DE60224592T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE60224592T 2001-03-01 2002-03-01 Polymorphe und andere kristalline Formen von cis-FTC Expired - Lifetime DE60224592T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US27256001P 2001-03-01 2001-03-01
US272560P 2001-03-01
US30960501P 2001-08-02 2001-08-02
US309605P 2001-08-02

Publications (2)

Publication Number Publication Date
DE60224592D1 true DE60224592D1 (de) 2008-02-21
DE60224592T2 DE60224592T2 (de) 2009-01-29

Family

ID=26955597

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60224592T Expired - Lifetime DE60224592T2 (de) 2001-03-01 2002-03-01 Polymorphe und andere kristalline Formen von cis-FTC
DE60207850T Expired - Lifetime DE60207850T2 (de) 2001-03-01 2002-03-01 Polymorphe und andere kristalline formen von cis-ftc

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60207850T Expired - Lifetime DE60207850T2 (de) 2001-03-01 2002-03-01 Polymorphe und andere kristalline formen von cis-ftc

Country Status (14)

Country Link
US (3) US6723728B2 (de)
EP (3) EP1574512B1 (de)
JP (4) JP5105689B2 (de)
KR (4) KR101015510B1 (de)
CN (4) CN1503796B (de)
AT (2) ATE312097T1 (de)
AU (1) AU2002335489B2 (de)
CA (4) CA2690137C (de)
CY (2) CY1107983T1 (de)
DE (2) DE60224592T2 (de)
DK (2) DK1389207T3 (de)
ES (3) ES2299950T3 (de)
PT (2) PT1574512E (de)
WO (1) WO2002070518A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2690137C (en) 2001-03-01 2012-11-13 Gilead Sciences, Inc. Polymorphic and other crystalline forms of cis-ftc
TWI244393B (en) * 2002-08-06 2005-12-01 Idenix Pharmaceuticals Inc Crystalline and amorphous forms of beta-L-2'-deoxythymidine
ATE398455T1 (de) 2003-01-14 2008-07-15 Gilead Sciences Inc Zusammensetzungen und verfahren zur antiviralen kombinationstherapie
US6943249B2 (en) 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
US6887855B2 (en) 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
US20060014949A1 (en) * 2004-07-13 2006-01-19 Supergen Inc. Compositions and formulations of decitabine polymorphs and methods of use thereof
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
WO2009005338A2 (en) * 2007-07-05 2009-01-08 Ultimorphix Technologies B.V. Solid forms ult-i, ult-2 and ult-3 of emtricitabine
EP2350065A1 (de) 2008-11-12 2011-08-03 Lupin Ltd. Neues polymorph von emtricitabin und verfahren zu dessen herstellung
US8710218B2 (en) 2009-07-15 2014-04-29 Lupin Limited Process for preparation of Efavirenz

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4476248A (en) 1983-02-28 1984-10-09 The Upjohn Company Crystallization of ibuprofen
US5684153A (en) 1984-08-16 1997-11-04 Beecham Group Plc Process for the preparation of purine derivatives
EP0141927B1 (de) 1983-08-18 1991-10-30 Beecham Group Plc Antivirale Guanin-Derivate
US5223263A (en) 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
CS264222B1 (en) 1986-07-18 1989-06-13 Holy Antonin N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them
WO1989002733A1 (en) 1987-09-22 1989-04-06 The Regents Of The University Of California Liposomal nucleoside analogues for treating aids
US5041449A (en) 1988-04-11 1991-08-20 Iaf Biochem International, Inc. 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
NZ228645A (en) 1988-04-11 1991-09-25 Iaf Biochem Int 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections
US6175008B1 (en) 1988-04-11 2001-01-16 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US5411947A (en) 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5194654A (en) 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
US5463092A (en) 1989-11-22 1995-10-31 Vestar, Inc. Lipid derivatives of phosphonacids for liposomal incorporation and method of use
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5914331A (en) 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US6069252A (en) 1990-02-01 2000-05-30 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers
US5700937A (en) 1990-02-01 1997-12-23 Emory University Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
AU7872491A (en) 1990-05-07 1991-11-27 Vical, Inc. Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs
EP0531452A4 (en) 1990-05-29 1993-06-09 Vical, Inc. Synthesis of glycerol di- and triphosphate derivatives
DK0533833T3 (da) 1990-06-13 1996-04-22 Arnold Glazier Phosphorprolægemidler
US5674849A (en) 1990-10-24 1997-10-07 Allelix Biopharmaceuticals Inc. Anti-viral compositions
US5149794A (en) 1990-11-01 1992-09-22 State Of Oregon Covalent lipid-drug conjugates for drug targeting
US5256641A (en) 1990-11-01 1993-10-26 State Of Oregon Covalent polar lipid-peptide conjugates for immunological targeting
US5543389A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization Covalent polar lipid-peptide conjugates for use in salves
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US6228860B1 (en) * 1990-11-13 2001-05-08 Biochem Pharma Inc. Substituted 1,3-oxathiolanes with antiviral properties
US5925643A (en) 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
US5444063A (en) 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5179104A (en) 1990-12-05 1993-01-12 University Of Georgia Research Foundation, Inc. Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides
IL100502A (en) 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
NZ241625A (en) * 1991-02-22 1996-03-26 Univ Emory 1,3-oxathiolane derivatives, anti-viral compositions containing such and method of resolving racemic mixture of enantiomers
GB9104740D0 (en) 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
IT1244501B (it) 1991-03-22 1994-07-15 Sigma Tau Ind Farmaceuti Derivati amminoacilici e oligopeptidici dell'allopurinolo dotati di attivita' immunostimolante e composizioni farmaceutiche che li contengono
WO1992018517A1 (en) 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
GB9110874D0 (en) 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
ZA923641B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9111902D0 (en) * 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
JPH07500573A (ja) 1991-07-12 1995-01-19 ネクススター・ファーマシューティカルズ・インコーポレイテッド 抗ウィルス性リポヌクレオシド：ｂ型肝炎の治療
US5554728A (en) 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
US6177435B1 (en) 1992-05-13 2001-01-23 Glaxo Wellcome Inc. Therapeutic combinations
WO1994026273A1 (en) 1993-05-12 1994-11-24 Hostetler Karl Y Acyclovir derivatives for topical use
GB9311709D0 (en) 1993-06-07 1993-07-21 Iaf Biochem Int Stereoselective synthesis of nucleoside analogues using bicycle intermediate
US5587362A (en) 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL113432A (en) 1994-04-23 2000-11-21 Glaxo Group Ltd Process for the diastereoselective synthesis of nucleoside analogues
US5808040A (en) 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
SE9500872L (sv) * 1995-03-10 1996-04-01 Tony Wiseby Anordning vid sikte för pilbåge
US5869461A (en) 1995-03-16 1999-02-09 Yale University Reducing toxicity of L-nucleosides with D-nucleosides
DE19543707A1 (de) * 1995-11-23 1997-05-28 Inst Neue Mat Gemein Gmbh Verfahren zum Konservieren von Papier
GB9525606D0 (en) 1995-12-14 1996-02-14 Iaf Biochem Int Method and compositions for the synthesis of dioxolane nucleosides with › - configuration
WO1998023285A1 (en) 1996-11-29 1998-06-04 Smithkline Beecham Plc Use of a combination of penciclovir and alpha-interferon in the manufacture of a medicament for the treatment of hepatitis b
TW318283B (en) 1996-12-09 1997-10-21 United Microelectronics Corp Multi-level read only memory structure and manufacturing method thereof
US6071922A (en) 1997-03-19 2000-06-06 Emory University Synthesis, anti-human immunodeficiency virus, and anti-hepatitis B virus activities of 1,3-oxaselenolane nucleosides
RU2439069C2 (ru) * 1998-08-12 2012-01-10 Гайлид Сайенсиз, Инк. Способ получения 1,3-оксатиолановых нуклеозидов
PT1119635E (pt) 1998-10-09 2012-07-24 Gilead Sciences Inc Sistemas não homogéneos para a resolução de misturas enantioméricas
CA2690137C (en) * 2001-03-01 2012-11-13 Gilead Sciences, Inc. Polymorphic and other crystalline forms of cis-ftc
US6600044B2 (en) * 2001-06-18 2003-07-29 Brantford Chemicals Inc. Process for recovery of the desired cis-1,3-oxathiolane nucleosides from their undesired trans-isomers

Also Published As

Publication number Publication date
US6723728B2 (en) 2004-04-20
US20090306114A1 (en) 2009-12-10
EP1903041A3 (de) 2008-04-23
JP2015028045A (ja) 2015-02-12
KR20040002871A (ko) 2004-01-07
CN102911165A (zh) 2013-02-06
CN1503796A (zh) 2004-06-09
ES2299950T3 (es) 2008-06-01
EP1574512B1 (de) 2008-01-09
CN102942563A (zh) 2013-02-27
DE60207850T2 (de) 2006-08-10
US20030060645A1 (en) 2003-03-27
KR20080065316A (ko) 2008-07-11
EP1574512A1 (de) 2005-09-14
PT1903041E (pt) 2015-06-23
KR101150250B1 (ko) 2012-06-12
CN102911165B (zh) 2016-08-17
CA2867970A1 (en) 2002-09-12
JP2004530660A (ja) 2004-10-07
ES2537007T3 (es) 2015-06-01
CN102911166B (zh) 2016-08-17
US7544692B2 (en) 2009-06-09
CN102911166A (zh) 2013-02-06
KR20100091265A (ko) 2010-08-18
AU2002335489B2 (en) 2008-06-05
CA2439831C (en) 2010-01-12
JP2013040192A (ja) 2013-02-28
EP1389207A1 (de) 2004-02-18
US8637535B2 (en) 2014-01-28
CY1107913T1 (el) 2013-09-04
KR100927024B1 (ko) 2009-11-17
CA2690137C (en) 2012-11-13
KR101015510B1 (ko) 2011-02-16
CA2788498A1 (en) 2002-09-12
KR20080065317A (ko) 2008-07-11
WO2002070518A1 (en) 2002-09-12
CA2690137A1 (en) 2002-09-12
JP5105689B2 (ja) 2012-12-26
EP1389207B1 (de) 2005-12-07
ATE312097T1 (de) 2005-12-15
CA2439831A1 (en) 2002-09-12
DK1389207T3 (da) 2006-04-18
DE60224592T2 (de) 2009-01-29
EP1903041A2 (de) 2008-03-26
US20050026934A1 (en) 2005-02-03
JP2009197005A (ja) 2009-09-03
EP1903041B1 (de) 2015-02-18
CY1107983T1 (el) 2013-09-04
DK1574512T3 (da) 2008-03-03
PT1574512E (pt) 2008-03-05
DE60207850D1 (de) 2006-01-12
CN1503796B (zh) 2012-07-04
ES2253544T3 (es) 2006-06-01
CA2788498C (en) 2016-02-16
ATE383355T1 (de) 2008-01-15

Similar Documents

Publication Publication Date Title
CY1107913T1 (el) Πολυμορφικες και αλλες κρυσταλλικες μορφες cis-ftc
NO20012966L (no) Kondenserte 1,2,4-tiadiazinderivater, deres fremstilling og anvendelse
MY138252A (en) Azabicyclic-substitud fused-heteroaryl compounds for the treatment of disease
DE60330895D1 (de) Verbindungen, die sich als inhibitoren vonjak und anderen proteinkinasen eignen
ZA200309887B (en) Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents.
WO2002017358A3 (en) Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists)
CY1110240T1 (el) Νεα παραγωγα 2η-πυριδαζινο-3-ονης, φαρμακευτικες συνθεσεις που τα περιεχουν και μεθοδος για την παρασκευη του δραστικου συστατικου
SE0102315D0 (sv) Compounds
SI1613304T1 (sl) Dpp-iv zaviralci
CA2388142A1 (en) Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase
HUP0402065A2 (hu) Heterobiciklikus szerkezetû hepatitis C vírus polimeráz inhibitorok, eljárás az elõállításukra és ezeket tartalmazó gyógyszerkészítmények
NZ609146A (en) Modified 4’-nucleosides as antiviral agents
HUP0500339A2 (hu) GSK3-mal kapcsolatos állapotok kezelésére használható aril-aminok, eljárás előállításukra, az ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
MY135841A (en) Novel benzodioxoles
WO2005063734A3 (de) Substituierte thiophene
MX2007000505A (es) Derivados de oxindol sustituidos y medicamentos que contienen los mismos.
IS6859A (is) Kristölluð form atorvastatíns
WO2006100081A3 (de) Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung
DE60003863D1 (de) Dioxocyclopentylhydroxamsäure
EA200701687A1 (ru) Гидрохлорид аморфного лерканидипина
WO2005004805A3 (en) Thermally stable crystalline epirubicin hydrochloride and method of making the same
SE0203825D0 (sv) Novel fused heterocycles and uses thereof
ATE501153T1 (de) Kristallisation von festen formen von clopidogreladditionssalzen
WO2004012687A3 (en) Crystalline and amorphous forms of beta-l-2'-deoxythymidine
JP2004500380A5 (de)

Legal Events

Date Code Title Description
8364 No opposition during term of opposition